3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
21
Rectal Neoplasms
10
Colonic Neoplasms
6
Pancreatic Neoplasms
4
Stomach Neoplasms
3
Neoplasm Metastasis
3
Adenocarcinoma Of Esophagus
3
Peritoneal Neoplasms
2
Neoplasms
2
Liver Neoplasms
2
Esophageal Neoplasms
2
Pancreatic Adenocarcinoma
1
Ovarian Neoplasms
1
Neuropathy, Painful
1
Neuralgia
1
Neoplasm Recurrence, Local
1
Malignant Solid Tumour
1
Locally Advanced Pancreatic Carcinoma(LAPC)
1
Gallbladder Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Disease Progression
1
Cold Hypersensitivity
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Carcinoma, Basal Cell
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Advanced Rectal Cancer
1
Advanced Primary Liver Cancer
1
Adenocarcinoma of the Lower Rectum
1
Interventions
Gemcitabine
13
Cisplatin
8
Capecitabine
8
Fluorouracil
5
pembrolizumab
4
Oxaliplatin
4
Sorafenib
3
Leucovorin
3
Erlotinib Hydrochloride
3
trametinib
2
regorafenib
2
durvalumab
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Magnetic Resonance Spectroscopy
2
Lapatinib
2
trifluridine tipiracil drug combination
1
tremelimumab
1
spartalizumab
1
seribantumab
1
olutasidenib
1
olaparib
1
devimistat
1
derazantinib
1
dehydroftorafur
1
cediranib
1
cabozantinib
1
Trifluridine
1
Trastuzumab
1
Therapeutics
1
Sutures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Bile Duct Neoplasms
×
Folfox protocol
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts